EBC-46: a protein kinase C activator with antineoplastic activity; isolated from Fontainea picrosperma; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
tigilanol tiglate : A diterpenoid natural product isolated from the kernels of the Australian blushwood tree (Fontainea picrosperma). It is approved as a veterinary pharmaceutical for the treatment of non-metastatic and non-resectable canine mast cell tumours. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Fontainea | genus | [no description available] | Euphorbiaceae | The spurge family of flowering plants in the order Malpighiales. The family consists of annual and perennial herbs and woody shrubs or trees. Members contain securinine.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 92135637 |
| CHEMBL ID | 3989916 |
| CHEBI ID | 194146 |
| MeSH ID | M000613237 |
| Synonym |
|---|
| ebc-46 |
| ebc 46 |
| 943001-56-7 |
| stelfonta |
| ebc46 |
| tigilanol tiglate |
| (1ar,1br,1cs,2ar,3s,3as,6as,6br,7r,8r,8as)-3,3a,6b-trihydroxy-2a-(hydroxymethyl)-1,1,5,7-tetramethyl-8a-{[(2s)-2-methylbutanoyl]oxy}-4-oxo-1a,1b,1c,2a,3,3a,4,6a,6b,7,8,8a-dodecahydro-1h-cyclopropa[5',6']benzo[1',2':7,8]azuleno[5,6-b]oxiren-8-yl (2e)-2-met |
| CHEBI:194146 |
| ebi-46 |
| (4s,5s,6r,7s,8r,9r,10s,11r,12r,13s,14r)-12-(2e)-2-methyl-2-enoatyl-13((2s)-2-methylbutyroyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one |
| tigilanol tiglate [mi] |
| tigilanol tiglate [inn] |
| R1ZJT87990 , |
| (1ar,1br,1cs,2ar,3s,3as,6as,6br,7r,8r,8as)-3,3a,6b-trihydroxy-2a-(hydroxymethyl)-1,1,5,7-tetramethyl-4-oxo-1,1a,1b,1c,2a,3,3a,4,6a,6b,7,8-dodecahydro-8ah-cyclopropa(5',6')benzo(1',2':7,8)azuleno(5,6-b)oxirene-8,8a-diyl 8a-((2s)-2-methylbutanoate) 8-((2e)- |
| tigilanol tiglate [who-dd] |
| 12-tigloyl-13-(2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tiglian-3-one |
| tigilanol tiglate [usan] |
| unii-r1zjt87990 |
| CHEMBL3989916 |
| tigilanol tiglate (usan/inn) |
| D11191 |
| DTXSID601029530 |
| AKOS040749650 |
| tigilanol tiglate injection |
| tigilanoli tiglas |
| stelfonta 1 mg/ml |
| toglato de tigilanol |
| tiglate de tigilanol |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Adverse events and quality of life were also assessed." | ( Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC-46). Burke-Schwarz, C; Campbell, JE; Clegg, D; De Ridder, TR; Elliot, EL; Geller, S; Gordon, V; Johannes, CM; Jones, PD; Kozak, W; Morton, J; Pittenger, ST; Pruitt, JB; Reddell, P; Riehl, J; Schmidt, PF; White, J; Wiest, ML, 2021) | 0.82 |
| " Adverse events typically were low grade, transient, and directly associated with TT's mode of action." | ( Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC-46). Burke-Schwarz, C; Campbell, JE; Clegg, D; De Ridder, TR; Elliot, EL; Geller, S; Gordon, V; Johannes, CM; Jones, PD; Kozak, W; Morton, J; Pittenger, ST; Pruitt, JB; Reddell, P; Riehl, J; Schmidt, PF; White, J; Wiest, ML, 2021) | 0.82 |
| Role | Description |
|---|---|
| antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
| plant metabolite | Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms. |
| protein kinase C agonist | An agonist that selectively binds to and activates a protein kinase C receptor |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| diterpenoid | Any terpenoid derived from a diterpene. The term includes compounds in which the C20 skeleton of the parent diterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups). |
| phorbol ester | Esters of phorbol, originally found in croton oil (from Croton tiglium, of the family Euphorbiaceae). A number of phorbol esters possess activity as tumour promoters and activate the mechanisms associated with cell growth. Some of these are used in experiments as activators of protein kinase C. |
| diester | A diester is a compound containing two ester groups. |
| organic heteropentacyclic compound | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1870997 | Cytotoxicity against PKC sensitive human K562 cells assessed as inhibition of cell growth measured after 7 days by Cell Titer Aqueous96 one solution reagent assay | |||
| AID1870996 | Induction of ROS production in human polymorphonuclear neutrophils incubated for 10 mins by DHE staining based fluorescence assay | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (45.18) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (40.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 3 (60.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||